Dr Harb

I am excited to join Carry the Torch walk this afternoon for the 9th year in support of Cancer Patients in our community at Riehle Plaza go Community Cancer Network!

The world of oncology drugs has changed in recent years, and so has the way drugs are tested and approved. We have witnessed a sea change in new drug approvals, and a commensurate increase in benefit for patients.

http://www.mwestonchapman.com/an-analysis-of-fda-oncology-drug-approvals-implications-for-patients-and-clinical-trials/

An analysis of FDA oncology drug approvals – implications for patients and clinical trials | Wes Chapman's Blog The Website of M. Weston Chapman

CAR T cells—their name comes from the chimeric antigen receptor, or CAR, added to help the immune cells target cancer cells—inspired the new work. CAR natural killer (CAR NK) cells could be safer, faster to produce, and cheaper, and they may work in situations where T cells falter.

Engineered natural killer cells may be the next great cancer immunotherapy Inspired by success with T cells, scientists equip other immune cells with cancer-homing protein

Immotherapy Resulted in Favorable 5-Year Survival Rates for Cancer Patients MedcalXpress.com A research team led by experts at the Bloomberg~Kimmel Institute for Cancer Immunotherapy at the Johns Hopkins Kimmel Cancer Center reports favorable five-year survival rates from the first multidose clinical trial of the immunotherapy drug nivolumab (anti-PD-1) as a treatment for p...

I am proud of my partner Dr Ajita Narayan. She is such a wonderful oncologist and hematologist. The best!

Verdi Oncology, Inc. Completes Partnership with Nashville Oncology Associates, PC.

Welcome Dr Karl Rogers and Dr Carl Willis to Verdi Oncology.

I am excited to partner with Dr Rogers and Dr Willis on clinical

Full Press Release:
https://www.prnewswire.com/news-releases/verdi-oncology-inc-completes-partnership-with-nashville-oncology-associates-pc-300880500.html

Verdi Oncology, Inc. Completes Partnership with Nashville Oncology Associates, PC NASHVILLE, Tenn., July 8, 2019 /PRNewswire/ -- Verdi Oncology, Inc., an oncology practice and clinical research management company, announced today it has...

A new investigational drug that blocks “Don’t Eat Me Signal” on Macrophages.

I am excited to announce Dosing of First Patient at Horizon Oncology & Research Center, a Verdi Oncology, Inc. Partner, in a Phase I Clinical Trial of TJC4, a Potentially Differentiated CD47 Antibody, for the Treatment of Cancers.

TJC4 is the second drug candidate from I-Mab's proprietary innovative pipeline to enter clinical studies in the US. Compared to other clinical stage CD47 antibodies, TJC4 is designed to improve the hematologic safety profile while exerting strong anti-tumor activities. It has the potential to be a best-in-class drug.

,

Full press release:
https://lnkd.in/ghfr2nG

All nurses are special people with their care and compassion especially oncology nurses who dedicate their life to help a person with cancer. Big shout to oncology nurses everywhere. I am very proud of our nurses who go above and beyond for our patients.

A drug tested in -1 at approved by the FDA for -Hodgkin .

The U.S. Food and Drug Administration granted accelerated approval to (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (a combination known as “BR”), to treat adult patients with diffuse large B-cell lymphoma ( ) that has progressed or returned after at least two prior therapies.

Polivy is a novel antibody-drug conjugate, and DLBCL is the most common type of non-Hodgkin lymphoma.

For list of trials at Horizon Oncology Center visit https://horizononcologycenter.com/clinical-trials/

https://www.fda.gov/news-events/press-announcements/fda-approves-first-chemoimmunotherapy-regimen-patients-relapsed-or-refractory-diffuse-large-b-cell

Tumor Mutational Burden ( ) is a marker for response to immunotherapy. We recommend to our patients with metastatic or advanced . We offer several that offer novel combination. To learn more contact us: https://horizononcologycenter.com/contact/

Examination of a cohort of patients with metastatic breast cancer and high mutational burden who were enrolled in the phase II Targeted Agent and Profiling Utilization Registry basket study shows that pembrolizumab monotherapy has antitumor activity in this population of heavily pretreated patients. http://www.onclive.com/link/5746

Great news for patients who have and mutation, a pill which biologically target BRCA. Patients are living longer with the cancer controlled. In some cases exceeded two years. For patients who have cancer of the pancreas it is recommended to check BRCA mutation among other genomic studies.

Olaparib Delays Progression in BRCA Pancreatic Cancer "It is our duty to search for this genetic mutation in all patients with metastatic pancreatic cancer so we can identify those people who can benefit," says Suzanne Cole, UT Southwestern Medical Center.

New Immunotherapy Treatment Removes All Tumors In Woman With Advanced Metastatic Breast Cancer

New Immunotherapy Treatment Removes All Tumors In Woman With Advanced Metastatic Breast Cancer A new immunotherapy approach using a patient's own tumor targeting T-cells has shown impressive results in a woman with metastatic breast cancer who only had months to live.

Colon cancer in young people between the age of 20 and 50 is rare but often overlooked because it is not suspected and when diagnosed it is more likely to be advanced stage.

Research study surveyed 1,195 colore**al cancer patients and survivors ages 20 to 49, mostly from the United States.

The research found that the majority of survey respondents, 57%, were diagnosed between the ages of 40 and 49; a third were diagnosed between the ages of 30 and 39; about 10% were diagnosed before age 30.

Colore**al cancer symptoms and screening guidelines

Symptoms of colore**al cancer include diarrhea or constipation; feeling that your bowel does not empty completely; blood in your stool; frequent gas pains or cramps; weight loss with no known reason; fatigue, and nausea or vomiting.
The American Cancer Society updated its colore**al cancer screening guidelines last year to recommend that adults at average risk get screened starting at age 45 instead of 50, as previously advised. Screening options can range from getting a highly sensitive f***l test annually to undergoing colonoscopy every 10 years

Colon cancer misdiagnosis in younger adults is a concern, study suggests While most colon and re**al cancer patients older than 50 are diagnosed in the early stages of disease, younger patients tend to be diagnosed at advanced stages, research suggests. Does this mean colore**al cancer initially is misdiagnosed in younger patients?

Women with human epidermal receptor 2–positive (HER2+) stage IV breast cancer who received surgery after systemic therapy were at a 44% reduced relative risk for death compared with women who did not undergo surgery.

Surgery Tied to Improved Survival in Stage IV Breast Cancer A retrospective analysis showed that for women with HER2+ stage IV breast cancer, surgery was associated with higher survival rates compared with women who did not undergo surgery.